FEATURES OF PATIENTS WITH THE MULTIPLE SENSITIZATION DIAGNOSTICS BEFORE ALLERGEN SPECIFIC IMMUNOTHERAPY WILL BE SET AND THE ASSESSMENT OF THE THERAPY RESULTS WITH THE LABORATORY METHODS

Cover Page

Abstract


Background: Due to the wide expansion of atopy, its early beginning, variety of forms, difficulty of specific pathogenetic treatment, and also high
cost of in vitro researches there is a need of diagnostic test systems development and optimization. Aim: To make the assessment of atopy diagnostics efficiency in children with a multiple allergy and the analysis of specific immunotherapy (ASIT) influence on immune markers level in serum for a choice of the most significant predictive indicator. Patients and methods: 457 children (mean age 8,9±4,3 years) with pollinosis symptoms that prevalence in spring period were tested with birch pollen allergens extract by detecting allergen-specific immunoglobulin E (sIgE) levels. Than patient witch showed positive sIgE level (243 children) were tested with expanded set of plant allergens (birch, alder, hazel, oak pollen, allergens of Rosaceae family and carrot) and set of birch pollen allergocomponents (Bet v1, Bet v2, Bet v4, Bet v6). From them 32 patients were treated with allergenspecific immunotherapy. Immunological assays were performed by indirect immunofluorescent method on ImmunoCAP250 (Sweden). Results: It was shown that birch allergens sIgE antibodies detection in patients with pollinosis allows to estimate sensitization degree to allergens of related trees and could predict their quantitative values. The oak allergens sIgE level is a good predictive marker of sIgE level to food plant derived allergens. And apple allergens sIgE concentration is closely assotiated with sIgE to fruit allergens of Rosacea family. Detection of sensitization to minor allergens in patient influences on therapy efficacy prognosis. Conclusion: sIgE detection to limited number of allergens (birch-oak-apple) is effective to sIgE value assessment in patient with allergy to plant causing allergens cross reactivity. Component-divided in vitro diagnostics directed on reveal of sensitization caused by minor allergens, is actual at the answer a question about ASIT validity and its efficiency. Component-divided in vitro diagnostics directed on reveal of sensitization caused by minor allergens, is actual at the answer a question about ASIT validity and its efficiency. Significant results of the therapy are shown after double course ASIT that also allows to reduce considerably production of sIgE antibodies to significant allergens, and cross reacting plant food allergens.


About the authors

M. A. Snovskaya

Scientific Centre of Children's Health, Moscow

Author for correspondence.
Email: snows@inbox.ru

Russian Federation

physician of Instrumental and Laboratory Diagnosis Department of CDC Research Institute of Preventive Pediatrics and Rehabilitation of SCCH

 

L. S. Namazova-Baranova

Scientific Centre of Children's Health, Moscow, Russian Federation

Email: namazova@nczd.ru

Russian Federation доктор медицинских наук, профессор, член-корреспондент РАМН, директор НИИ профилактической педиатрии и восстановительного лечения Научного центра здоровья детей Адрес: 119991, Москва, Ломоносовский пр-т, д. 2, стр. 1, тел.: +7 (495) 967-14-20

E. L. Semikina

Scientific Centre of Children's Health, Moscow, Russian Federation

Email: semikinaelena@yandex.ru
доктор медицинских наук, заведующая гематологической группой Централизованной клинико-диагностической лаборатории Научного центра здоровья детей Адрес: 119991, Москва, Ломоносовский пр-т, д. 2, стр. 1, тел.: +7 (495) 967-14-20

O. V. Kozhevnikova

Scientific Centre of Children's Health, Moscow, Russian Federation

Email: fd@nczd.ru

Russian Federation кандидат медицинских наук, заведующая отделением инструментальной и лабо- раторной диагностики КДЦ НИИ профилактической педиатрии и восстановительного лечения Научного центра здоровья детей Адрес: 119991, Москва, Ломоносовский пр-т, д. 2, стр. 1, тел.: +7 (495) 967-14-20

References

  1. Ковальчук Л.В., Ганковская Л.В., Мешкова Р.Я. Клиническая иммунология и аллергология с основами общей иммунологии: учебник. М.: ГЭОТАР-Медиа. 2011. 640 с.
  2. Аллергология и иммунология: клинические рекомендации для педиатров. 3-е изд., доп. Под общ. ред. А.А. Баранова, Р.М. Хаитова. М.: Союз педиатров России. 2011. 254 с.
  3. Аллергия у детей — от теории к практике. Монография. Серия: «Современная педиатрия: от теории — к практике». Под ред. Л.С. Намазовой-Барановой. М.: Союз педиатров России. 2011. 668 с.
  4. Osterballe M., Hansen T.K., Mortz C.G., Host A, Bindslev-Jensen C. The prevalence of food hypersensitivity in an unselected population of children and adults. Pediatr. Allergy. Immunol. 2005; 16: 567–573.
  5. Bartra J., Sastre J., Cuvillo del A., Montoro J., Jáuregui I., Dávila I., Ferrer M., Mullol M., Valero A. From Pollinosis to Digestive Allergy. Aller. Clin. Immunol. 2009; 19 (Suppl. 1): 3–10.
  6. Sancho A.I., Wangorsch A., Jensen B.M., Watson A., Alexeev Y., Johnson P.E., Mackie A.R., Neubauer A., Reese G., BallmerWeber B., Hoffmann-Sommergruber K., Skov P.S., Vieths S., Mills E.N. Responsiveness of the major birch allergen Bet v 1 scaffold to the gastric environment: impact on structure and allergenic activity. Mol.Nutr. & Food Res. 2011; 55 (11): 1690–1699.
  7. Ferreira F., Hawranek T., Gruber P., Wopfner N., Mari A. Allergic cross-reactivity: from gene to the clinic. Allerg. J. 2004; 59: 243–267.
  8. Goikoetxea M.J., Cabrera-FreitagP., Sanz M.L., FernándezBenítez M. The importance of in vitro component-resolved diagnosis in paediatric patients. Publ. en Allerg. Imm. (Madr). 2010; 38: 37–40.
  9. Vieths S., Scheurer S., Ballmer-Weber B. Current understanding of cross-reactivity of food allergens and pollen. Ann. N.Y. Acad. Sci. 2002; 964: 47–68.
  10. Mahler V., Fischer S., Heiss S., Duchene M., Kraft D., Valenta R. cDna cloning and characterization of a cross-reactive birch pollen allergen: identification as a pectin esterase. Int. Arch. Allergy Immunol. 2001; 124: 64–66.
  11. Moreno-Aguilar C., Improving pollen immunotherapy: minor allergens and panallergens. Allerg. Imm. (Madrid). 2008; 36: 26–30.
  12. Asero R. Component-resolved diagnosis-assisted prescription of allergen-specific immunotherapy: a practical guide. Eur. Ann. Allergy Clin. Immunol. 2012; 44 (5): 183–187.
  13. Gadisseur R., Chapelle J.P., Cavalier E. A new tool in the field of in-vitro diagnosis of allergy: preliminary results in the comparison of ImmunoCAP© 250 with the ImmunoCAP© ISAC. Clin. Chem. Lab. Med. 2011; 49 (2): 277–280.
  14. Fall B.I., Niessner R. Detection of known allergen-specific IgE antibodies by immunological methods. Methods Mol. Biol. 2009; 509: 107–122.
  15. Курбачева О.М. Сублингвальная аллергенспецифическая иммунотерапия — метод системного лечения атопических заболеваний. Росс. аллергол. журн. 2006; 6: 3–9.

Statistics

Views

Abstract - 334

PDF (Russian) - 859

Cited-By


Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

PlumX

Dimensions



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies